ArticleJTCVS open2026
Long-term outcomes of surgical aortic valve replacement using a third-generation stented bovine pericardial bioprosthesis in 1907 patients.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This large, single-center evaluation presents long-term survival, reintervention, and echocardiographic outcomes after implantation of a third-generation supra-annular stented bovine pericardial aortic valve with a proprietary anticalcification treatment. Methods: After excluding patients with ventricular assist devices, congenital repairs, and heart transplants, 1907 patients underwent aortic valve replacement with this bioprosthetic valve between August 2010 and September 2023. Primary outcomes were freedom from all-cause mortality and reintervention for structural valve deterioration. Secondary outcomes included mean transprosthetic gradient and Valve Academic Research Consortium 3-defined severe hemodynamic valve dysfunction. Results: Among 1907 patients included, 30-day mortality was 2.8% (N = 54), stroke occurred in 2.8% (N = 53), and a permanent pacemaker was implanted in 3.3% (N = 62). Echocardiographic follow-up was available in 90.46% of patients (mean follow-up: 4 years; total 6557 echocardiograms reviewed). Overall mean transprosthetic gradient was 11.76 ± 6.52 mm Hg, 12.87 ± 7.52 mm Hg, 16.10 ± 11.02 mm Hg, and 16.01 ± 8.31 mm Hg at 1, 5, 10, and 12 years, respectively. Overall survival was 93.25%, 77.62%, 47.99% and 37.84% at 1, 5, 10, and 12 years, respectively. Freedom from stage 3 hemodynamic valve dysfunction was 99.08%, 85.75%, and 64.32% at 5, 10, and 12 years, respectively. Structural valve deterioration-related reintervention occurred in 2.7% of patients (N = 51), with freedom from reintervention at 98.32%, 90.80%, and 85.13% at 5, 10, and 12 years, respectively. Conclusions: Long-term outcomes of this bioprosthetic valve are characterized by excellent overall survival, low structural valve deterioration rates, and sustained hemodynamic performance through 12 years of follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.